Chromosome 1p and 19q Deletions in Glioblastoma Multiforme

被引:23
作者
Kaneshiro, David [2 ]
Kobayashi, Taisei [1 ]
Chao, Samuel T. [1 ]
Suh, John [1 ]
Prayson, Richard A. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA
关键词
glioblastoma multiforme (GBM); fluorescent in situ hybridization (FISH); chromosome; 1p; 19q; PHASE-III TRIAL; ANAPLASTIC OLIGODENDROGLIOMAS; GENETIC ALTERATIONS; SURVIVAL; GLIOMAS; PREDICTORS; GENOTYPE; IMPACT; OLIGOASTROCYTOMAS; PROCARBAZINE;
D O I
10.1097/PAI.0b013e3181a2c6a4
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Context: Deletions on chromosomes 1p and 19q have been shown to correlate with prognosis and chemosensitivity in anaplastic oligodendrogliomas. In glioblastoma multiforme (GBM), the impact on prognosis of these alterations in GBM is unclear. Objective: The purpose of this study was to identify patients with GBM who had evidence of 1p or 19q deletions by flourescence in situ hybridization, and correlate these results with clinical findings and survival. Design: Three hundred thirty-seven GBM resected between 2001 and 2006 were evaluated using flourescence in situ hybridization to identify deletions on chromosomes 1p and 19q. Cox regression was used to compare survival between these 2 groups and a control group of 1p and 19q intact tumors. Result: Seventeen (5.1%) patients (9 males; mean age at diagnosis = 61y, range: 35 to 84y) were found to have 1p deletions; 8 patients (47.1%) received chemotherapy and 13 patients received radiation therapy. The mean survival for this group was 10.8 months (range: 1 to 50 mo). Eighteen (5.3%) patients (11 females; mean = 56 y, range: 25 to 76 y) had 19q deletions; 9 patients (50%) received chemotherapy and 8 patients were known to have had radiation therapy. The mean survival of this group was 8.4 months (range: 1 to 17 mo). A control group of 20 patients (13 males; mean = 60y, range: 40 to 80 y) was selected, 8 patients (40%) of who received chemotherapy and 12 patients were known to have had radiation therapy. The mean survival in this group was found to be 16.4 months (1 to 59 mo). Nine (3.7%) tumors had codeletions of 1p and 19q and were not evaluated in this study. Isolated 1p and 19q deletions did not significantly correlate with survival. Adjusting for sex, age, and chemotherapy, the 19q-deleted group had a significantly lower survival (hazard ratio = 2.8, P = 0.025) than the other groups. Conclusions: The incidence of isolated 1p or 19q deletions among GBM in the current study was 6.2% and 5.3%, respectively. In contrast to anaplastic oligodendrogliomas, 1p and 19q deletions alone were not found to improve survival of patients with GBM; however, when adjusted for age, sex, and chemotherapy, 19q deletions seem to negatively impact survival.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 22 条
  • [11] Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
    Ino, Y
    Zlatescu, MC
    Sasaki, H
    MacDonald, DR
    Stemmer-Rachamimov, AO
    Jhung, S
    Ramsay, DA
    von Deimling, A
    Louis, DN
    Cairncross, JG
    [J]. JOURNAL OF NEUROSURGERY, 2000, 92 (06) : 983 - 990
  • [12] Jenkins RB, 2001, AM J CLIN ONCOL-CANC, V24, P506
  • [13] The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making
    Kanner, AA
    Staugaitis, SM
    Castilla, EA
    Chernova, O
    Prayson, RA
    Vogelbaum, MA
    Stevens, G
    Peereboom, D
    Suh, J
    Lee, SY
    Tubbs, RR
    Barnett, GH
    [J]. JOURNAL OF NEUROSURGERY, 2006, 104 (04) : 542 - 550
  • [14] Whole-genome analysis of human astrocytic tumors by comparative genomic hybridization.
    Maruno M.
    Ninomiya H.
    Ghulam Muhammad A.K.
    Hirata M.
    Kato A.
    Yoshimine T.
    [J]. Brain Tumor Pathology, 2000, 17 (1) : 21 - 27
  • [15] Loss of heterozygosity on chromosome 19 in secondary glioblastomas
    Nakamura, M
    Yang, F
    Fujisawa, H
    Yonekawa, Y
    Kleihues, P
    Ohgaki, H
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (06) : 539 - 543
  • [16] Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
    Ohgaki, H
    Kleihues, P
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2005, 64 (06) : 479 - 489
  • [17] Impact of genotype and morphology on the prognosis of glioblastoma
    Schmidt, MC
    Antweiler, S
    Urban, N
    Mueller, W
    Kuklik, A
    Meyer-Puttlitz, B
    Wiestler, OD
    Louis, DN
    Fimmers, R
    von Deimling, A
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (04) : 321 - 328
  • [18] Genetic analyses for predictors of radiation response in glioblastoma
    Shih, HA
    Betensky, RA
    Dorfman, MV
    Louis, DN
    Loeffler, JS
    Batchelor, TT
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 704 - 710
  • [19] Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
    Smith, JS
    Perry, A
    Borell, TJ
    Lee, HK
    O'Fallon, J
    Hosek, SM
    Kimmel, D
    Yates, A
    Burger, PC
    Scheithauer, BW
    Jenkins, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 636 - 645
  • [20] Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
    van den Bent, Martin J.
    Carpentier, Antoine F.
    Brandes, Alba A.
    Sanson, Marc
    Taphoorn, Martin J. B.
    Bernsen, Hans J. J. A.
    Frenay, Marc
    Tijssen, Cees C.
    Grisold, Wolfgang
    Sipos, Laslo
    Haaxma-Reiche, Hanny
    Kros, Johannes M.
    van Kouwenhoven, Mathilde C. M.
    Vecht, Charles J.
    Allgeier, Anouk
    Lacombe, Denis
    Gorlia, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2715 - 2722